+

WO2003074069A3 - Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1) - Google Patents

Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1) Download PDF

Info

Publication number
WO2003074069A3
WO2003074069A3 PCT/EP2003/001838 EP0301838W WO03074069A3 WO 2003074069 A3 WO2003074069 A3 WO 2003074069A3 EP 0301838 W EP0301838 W EP 0301838W WO 03074069 A3 WO03074069 A3 WO 03074069A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
fpr
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2003/001838
Other languages
English (en)
Other versions
WO2003074069A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to AU2003214072A priority Critical patent/AU2003214072A1/en
Publication of WO2003074069A2 publication Critical patent/WO2003074069A2/fr
Publication of WO2003074069A3 publication Critical patent/WO2003074069A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un FPR1 humain associé aux maladies hématologiques, aux maladies cardio-vasculaires, aux troubles du système nerveux périphérique et central, aux BPCO, à l'asthme, aux maladies inflammatoires et au cancer. Cette invention fournit aussi des épreuves biologiques permettant d'identifier des composés utiles au traitement ou à la prévention de maladies hématologiques, de maladies cardio-vasculaires, de troubles du système nerveux périphérique et central, des BPCO, de l'asthme, des maladies inflammatoires et du cancer. Cette invention concerne également des composés qui se lient à et/ou activent ou inhibent l'activité de FPR1 ainsi que des compositions pharmaceutiques contenant ces composés.
PCT/EP2003/001838 2002-03-07 2003-02-24 Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1) WO2003074069A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003214072A AU2003214072A1 (en) 2002-03-07 2003-02-24 Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02005202 2002-03-07
EP02005202.3 2002-03-07

Publications (2)

Publication Number Publication Date
WO2003074069A2 WO2003074069A2 (fr) 2003-09-12
WO2003074069A3 true WO2003074069A3 (fr) 2004-04-01

Family

ID=27771845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001838 WO2003074069A2 (fr) 2002-03-07 2003-02-24 Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1)

Country Status (2)

Country Link
AU (1) AU2003214072A1 (fr)
WO (1) WO2003074069A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102173673B1 (ko) 2018-05-04 2020-11-03 사회복지법인 삼성생명공익재단 기관지 폐 이형성증 (bpd) 예방 또는 치료용 물질 스크리닝 방법

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003267347A1 (en) * 2003-09-10 2005-03-29 Galapagos Genomics N.V. Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
JP2007516434A (ja) * 2003-11-07 2007-06-21 アカディア ファーマシューティカルズ インコーポレイティド リポキシン受容体ｆｐｒｌ１の、疼痛および炎症の治療に有効な化合物を識別する手段としての使用
US7659091B2 (en) 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
US7662571B2 (en) 2005-07-14 2010-02-16 Nourheart Inc. Mitochondrial markers of ischemia
US20080008694A1 (en) * 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
EP2490021A1 (fr) * 2011-02-18 2012-08-22 Biotempt B.V. Modulateurs de signalisation PRR et GPCR
PL2809810T3 (pl) * 2012-01-06 2020-07-27 Viomics Inc. Układ i sposób wykrywania rna zmienionych przez raka płuca w krwi obwodowej
US10328075B2 (en) 2015-02-04 2019-06-25 Baker Heart and Diabetes Institute Method of treatment and compounds for use therein
US12031976B2 (en) 2018-05-04 2024-07-09 Samsung Life Public Welfare Foundation Screening method for therapeutic substance for preventing or treating bronchopulmonary dysplasia (BPD)
CN115317611B (zh) * 2022-07-05 2023-07-28 天津天海新域生物科技有限公司 Fpr1拮抗剂t-0080在制备用于治疗动脉粥样硬化症药物中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BECKER ELMER L ET AL: "Broad immunocytochemical localization of the formylpeptide receptor in human organs, tissues, and cells.", CELL & TISSUE RESEARCH, vol. 292, no. 1, April 1998 (1998-04-01), pages 129 - 135, XP002249588, ISSN: 0302-766X *
KEITOKU MITSUMASA ET AL: "FMLP actions and its binding sites in isolated human coronary arteries.", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 29, no. 3, 1997, pages 881 - 894, XP002249985, ISSN: 0022-2828 *
LE YINGYING ET AL: "Receptors for chemotactic formyl peptides as pharmacological targets.", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 2, no. 1, January 2002 (2002-01-01), pages 1 - 13, XP002249587, ISSN: 1567-5769 *
ROBBINS M J ET AL: "Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C)", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 1, no. 67, 1 July 2000 (2000-07-01), pages 8 - 18, XP002242592, ISSN: 0888-7543 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102173673B1 (ko) 2018-05-04 2020-11-03 사회복지법인 삼성생명공익재단 기관지 폐 이형성증 (bpd) 예방 또는 치료용 물질 스크리닝 방법

Also Published As

Publication number Publication date
WO2003074069A2 (fr) 2003-09-12
AU2003214072A8 (en) 2003-09-16
AU2003214072A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
WO2003082314A3 (fr) Diagnostics et therapies pour maladies liees a un recepteur de type 1 de peptides n-formyl (fprl1)
WO2003074069A3 (fr) Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1)
WO2003081258A3 (fr) Diagnostics et elements therapeutiques pour maladies associees au recepteur secretagogue de l'hormone de croissance (ghs)
WO2004042389A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees a la phosphodiesterase 4d (pde4d) humaine
WO2003093816A3 (fr) Diagnostics et therapeutiques pour lutter contre des maladies associees au recepteur de l'oxytocine (oxtr)
WO2004080373A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 2 active par la proteinase (par2) couple aux proteines g
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
WO2003065044A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a gpr72
WO2003095967A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur 9 des chimiokines (ccr9)
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2003096020A3 (fr) Diagnostic et traitement de maladies liees au recepteur 8 des chimiokines (ccr8)
WO2003100433A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 3 de l'arginine vasopressine (avpr3)
WO2003083135A3 (fr) Diagnostique et therapie de maladies associees au recepteur 2 du neuropeptide ff (npff2)
WO2003066077A3 (fr) Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)
WO2003080098A3 (fr) Diagnostics et therapeutiques associes au recepteur 2 du peptide de formyle humain
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2004038407A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur 12 humain couple a la proteine g (gpr12)
WO2003081257A3 (fr) Moyens diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur 1 du neuropeptide ff (npff1)
WO2003100435A3 (fr) Procede pour diagnostiquer et traiter des maladies associees au recepteur de neuromedine u2 (nmu2)
WO2003080100A3 (fr) Diagnostic et therapie des maladies associees au recepteur 63 couple a la proteine g chez homo sapiens (gpr63)
WO2004015427A3 (fr) Methodes diagnostiques et therapeutiques s'adressant a des maladies associees au recepteur 19 couple a la proteine g (gpr19)
WO2004015422A3 (fr) Diagnostic et traitement de maladies associees au recepteur 1 couple a la proteine g (ogr-1) du cancer de l'ovaire
WO2003080097A3 (fr) Methodes diagnostiques et therapeutiques relatives a des maladies associees au recepteur 7 couple a la proteine g humaine (gpr7)
WO2003100434A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 2 de l'arginine vasopressine (avpr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载